Xiangxue Pharmaceutical Co Ltd (300147):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Xiangxue Pharmaceutical Co Ltd (300147) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9406
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Xiangxue Pharmaceutical Co Ltd (XPH) is a pharmaceutical company that manufactures and distributes drugs and medicines. The company’s products include drugs, Chinese medicine pieces, medical instruments, health products and medicinal drinks, among others. It also provides healthcare supplements, Chinese herbal medicine and pharmaceutical medicines, among others. XPH offers services such as industrial chain services, research and development services, procurement, manufacturing, delivering services and distribution services, among others. The company provides its products and services to healthcare and medical care sectors. It has its operations in Guangdong, Beijing, Shanxi, Sichuan, Chongqing, Anhui, Yunnan and Ningxia, China. XPH is headquartered in Guangzhou, China.

Xiangxue Pharmaceutical Co Ltd (300147) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Xiangxue Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Xiangxue Pharma Signs Agreement with GE Medical Systems Trade & Development 12
Xiangxue Pharma Plans to Form Joint Venture in Guangzhou City 13
Licensing Agreements 14
Xiangxue Pharma Enters into Licensing Agreement with Kinex Pharma for KX02 14
Equity Offering 16
Xiangxue Pharma Raises USD259 Million in Rights Offering of Shares 16
Debt Offering 17
Xiangxue Pharmaceutical Raises USD31.7 Million in Public Offering of Bonds 17
Xiangxue Pharma Raises USD75.6 Million in Public Offering of Bonds 18
Xiangxue Pharma Plans to Raise up to USD75.3 Million in Private Placement of Bonds Due 2022 19
Xiangxue Pharma Raises USD90.2 Million in Public Offering of Bonds 20
Xiangxue Pharma Plans to Raise up to USD188.5 Million in Public Offering of Bonds 21
Xiangxue Pharma Raises USD112 Million in First Tranche Public Offering of 3.39% Notes Due 2017 22
Xiangxue Pharma Announces Private Placement Of Bonds Due 2017 For US$86.1 Million 23
Xiangxue Pharma Announces Public Offering Of Corporate Bonds For Up To US$95.05 Million 24
Acquisition 25
Xiangxue Pharma Plans to Acquire Stake in a Biotechnology Firm for USD7.1 Million 25
Xiangxue Pharma to Acquire 60% Stake in Guangzhou Based Pharma Company 26
Xiangxue Pharma Plans to Acquire 55% Stake in Hubei Ji day Chinese Herbal Medicine for USD55 Million 27
Xiangxue Pharma To Acquire 70% Stake In China-Based Company For US$73.7 Million 28
Xiangxue Pharma Plans To Acquire 25% Stake In China-Based Company For US$0.03 Million 29
Xiangxue Pharma Acquires 52% Stake In China-Based Company For US$4.1 Million 30
Xiangxue Pharma Plans To Acquire 7.98% Stake In China-Based Company For US$2.4 Million 31
Xiangxue Pharmaceutical Co Ltd – Key Competitors 32
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Other Significant Developments 34
Jun 07, 2018: GE Healthcare FlexFactory Helps XPH Scale Up Industrialization of TCR T-Cell Immunotherapy Drugs 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Xiangxue Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Xiangxue Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Xiangxue Pharma Signs Agreement with GE Medical Systems Trade & Development 12
Xiangxue Pharma Plans to Form Joint Venture in Guangzhou City 13
Xiangxue Pharma Enters into Licensing Agreement with Kinex Pharma for KX02 14
Xiangxue Pharma Raises USD259 Million in Rights Offering of Shares 16
Xiangxue Pharmaceutical Raises USD31.7 Million in Public Offering of Bonds 17
Xiangxue Pharma Raises USD75.6 Million in Public Offering of Bonds 18
Xiangxue Pharma Plans to Raise up to USD75.3 Million in Private Placement of Bonds Due 2022 19
Xiangxue Pharma Raises USD90.2 Million in Public Offering of Bonds 20
Xiangxue Pharma Plans to Raise up to USD188.5 Million in Public Offering of Bonds 21
Xiangxue Pharma Raises USD112 Million in First Tranche Public Offering of 3.39% Notes Due 2017 22
Xiangxue Pharma Announces Private Placement Of Bonds Due 2017 For US$86.1 Million 23
Xiangxue Pharma Announces Public Offering Of Corporate Bonds For Up To US$95.05 Million 24
Xiangxue Pharma Plans to Acquire Stake in a Biotechnology Firm for USD7.1 Million 25
Xiangxue Pharma to Acquire 60% Stake in Guangzhou Based Pharma Company 26
Xiangxue Pharma Plans to Acquire 55% Stake in Hubei Ji day Chinese Herbal Medicine for USD55 Million 27
Xiangxue Pharma To Acquire 70% Stake In China-Based Company For US$73.7 Million 28
Xiangxue Pharma Plans To Acquire 25% Stake In China-Based Company For US$0.03 Million 29
Xiangxue Pharma Acquires 52% Stake In China-Based Company For US$4.1 Million 30
Xiangxue Pharma Plans To Acquire 7.98% Stake In China-Based Company For US$2.4 Million 31
Xiangxue Pharmaceutical Co Ltd, Key Competitors 32
Xiangxue Pharmaceutical Co Ltd, Subsidiaries 33

List of Figures
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Xiangxue Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Xiangxue Pharmaceutical Co Ltd (300147):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Medidata Solutions Inc (MDSO):製薬・医療:M&Aディール及び事業提携情報
    Summary Medidata Solutions Inc (Medidata) is a provider of cloud based solutions for life sciences sectors. It offers wide range of advanced tools for data and analytics, planning, data capture, study management, monitoring, payments, and platform services. The company offers technology and data ana …
  • Zensar Technologies Limited (ZENSARTECH):企業の財務・戦略的SWOT分析
    Zensar Technologies Limited (ZENSARTECH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Microbot Medical Inc (MBOT):企業の財務・戦略的SWOT分析
    Summary Microbot Medical Inc (Microbot), formerly StemCells Inc, is a pre-clinical medical device company that researches, designs and develops micro-robotics assisted medical technologies for minimally invasive surgeries. The company’s product candidates comprises Self Cleaning Shunt, intended for …
  • AiVita Biomedical Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary AiVita Biomedical Inc (AiVita) is a biotechnology company developing novel stem cell technologies to develop cell-based treatments and healthcare products for the treatment of cancer, vision loss, and skincare formulations. Its lead therapeutic candidate is a patient-specific immunotherapy f …
  • Bisalloy Steel Group Ltd:企業の戦略・SWOT・財務情報
    Bisalloy Steel Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Bisalloy Steel Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Medical Prognosis Institute AS (MPI):医療機器:M&Aディール及び事業提携情報
    Summary Medical Prognosis Institute A/S (MPI) is a precision medicine provider that offers cancer treatment solutions. The company offers drug response prediction platforms that provide tools for rationalized drug development and personalized medicine. It offers lead compound selection, drug rescue …
  • Bolsas y Mercados Espanoles SA (BME):企業の財務・戦略的SWOT分析
    Summary Bolsas y Mercados Espanoles SA (BME) is an investment service provider that operates financial system. The company is an operator of financial systems. It offers services, products and advanced trading and global market access systems to issuers, intermediaries and investors. BME also offers …
  • Lansen Pharmaceutical Holdings Ltd (503):企業の財務・戦略的SWOT分析
    Summary Lansen Pharmaceutical Holdings Ltd (Lansen), a subsidiary of Cathay International Holdings Ltd is a pharmaceutical that develops, produces and sales specialty prescription western pharmaceuticals for the treatment of rheumatic diseases. The company’s products comprise specialist medicine, Ch …
  • RCI Banque SA:企業の戦略的SWOT分析
    RCI Banque SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Toyota Industries Corp (6201):企業の財務・戦略的SWOT分析
    Toyota Industries Corp (6201) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Sims Metal Management Ltd:企業の戦略・SWOT・財務情報
    Sims Metal Management Ltd - Strategy, SWOT and Corporate Finance Report Summary Sims Metal Management Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Correvio Pharma Corp (CORV):企業の財務・戦略的SWOT分析
    Correvio Pharma Corp (CORV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Sanyo Electric Co Ltd:企業のM&A・事業提携・投資動向
    Sanyo Electric Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sanyo Electric Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Biolife Solutions Inc (BLFS):企業の財務・戦略的SWOT分析
    Summary Biolife Solutions Inc (BioLife Solutions) is a developer, manufacturer and supplier of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media for cells and tissues. The company offers serum-free and protein-free solutions, which are formulated to red …
  • OCON Medical Ltd:企業の製品パイプライン分析2018
    Summary OCON Medical Ltd (OCON Medical) is a manufacturer of women’s health products. The company provides leverages intrauterine technology to develop contraceptive intrauterine devices for women. It develops IUB SCu300, an advanced intrauterine device that is compatible with the uterine cavity. OC …
  • Stora Enso Oyj (STERV):企業の財務・戦略的SWOT分析
    Stora Enso Oyj (STERV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Jones Packaging Inc.:企業の戦略的SWOT分析
    Jones Packaging Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Intermountain Healthcare Inc-製薬・医療分野:企業M&A・提携分析
    Summary Intermountain Healthcare Inc (Intermountain Healthcare) is a non-profit health care system. It provides health care services to Utah and Southeastern Idaho residents. It offers a wide range of clinical programs covering cardiovascular, intensive medicine, primary care, pediatric specialties, …
  • Starkey Hearing Technologies Inc:企業の戦略的SWOT分析
    Starkey Hearing Technologies Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Credito Emiliano SpA:企業の戦略・SWOT・財務分析
    Credito Emiliano SpA - Strategy, SWOT and Corporate Finance Report Summary Credito Emiliano SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆